Yusong Ye, Shu Huang, Xiaohong Wang, Wensen Ren, Xiaomin Shi, Sha Liu, Wei Zhang, Lei Shi, Muhan Lü, Xiaowei Tang
{"title":"Association between lactate-to-albumin ratio and all-cause mortality in cirrhosis patients: Analysis of the MIMIC-IV database.","authors":"Yusong Ye, Shu Huang, Xiaohong Wang, Wensen Ren, Xiaomin Shi, Sha Liu, Wei Zhang, Lei Shi, Muhan Lü, Xiaowei Tang","doi":"10.1016/j.medine.2025.502145","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study evaluates the predictive value of the lactate/albumin ratio (LAR) for all-cause mortality in cirrhosis patients.</p><p><strong>Design: </strong>Retrospective observational study.</p><p><strong>Setting: </strong>Intensive care unit (ICU).</p><p><strong>Patients or participants: </strong>626 first-time ICU-admitted cirrhosis patients in the USA (MIMIC-IV v2.2).</p><p><strong>Interventions: </strong>None.</p><p><strong>Main variables of interest: </strong>LAR index, 28-day, and 90-day all-cause mortality.</p><p><strong>Results: </strong>Of 626 patients (60.86% male), 27.80% and 39.14% died within 28 and 90 days, respectively. Multivariate Cox analysis showed a significant association between higher LAR and mortality. Adjusted for confounders, elevated LAR increased the 28-day mortality risk [HR: 1.31 (1.21-1.42), P < 0.001]. A restricted cubic spline analysis revealed non-linear relationships between LAR and mortality. For 28-day mortality, the inflection point was 1.583: below this, HR was 2.29 (95% CI: 1.61-3.27, P < 0.001); above, HR was 1.16 (95% CI: 1.02-1.31, P = 0.021; P = 0.002). For 90-day mortality, the inflection point was 1.423: below, HR was 1.60 (95% CI: 1.04-2.47, P = 0.033); above, HR was 0.94 (95% CI: 0.75-1.16, P = 0.542; P = 0.012).</p><p><strong>Conclusions: </strong>LAR predicts 28-day and 90-day mortality with a segmented effect. An LAR ≥1.583 signals high 28-day mortality risk, necessitating intensified monitoring and potential ICU admission. For 90-day mortality, LAR near 1.423 serves as an early warning for high-risk patients and guides interventions. Continuous LAR monitoring aids management, but prospective studies are needed to confirm clinical utility.</p>","PeriodicalId":94139,"journal":{"name":"Medicina intensiva","volume":" ","pages":"502145"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina intensiva","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medine.2025.502145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study evaluates the predictive value of the lactate/albumin ratio (LAR) for all-cause mortality in cirrhosis patients.
Design: Retrospective observational study.
Setting: Intensive care unit (ICU).
Patients or participants: 626 first-time ICU-admitted cirrhosis patients in the USA (MIMIC-IV v2.2).
Interventions: None.
Main variables of interest: LAR index, 28-day, and 90-day all-cause mortality.
Results: Of 626 patients (60.86% male), 27.80% and 39.14% died within 28 and 90 days, respectively. Multivariate Cox analysis showed a significant association between higher LAR and mortality. Adjusted for confounders, elevated LAR increased the 28-day mortality risk [HR: 1.31 (1.21-1.42), P < 0.001]. A restricted cubic spline analysis revealed non-linear relationships between LAR and mortality. For 28-day mortality, the inflection point was 1.583: below this, HR was 2.29 (95% CI: 1.61-3.27, P < 0.001); above, HR was 1.16 (95% CI: 1.02-1.31, P = 0.021; P = 0.002). For 90-day mortality, the inflection point was 1.423: below, HR was 1.60 (95% CI: 1.04-2.47, P = 0.033); above, HR was 0.94 (95% CI: 0.75-1.16, P = 0.542; P = 0.012).
Conclusions: LAR predicts 28-day and 90-day mortality with a segmented effect. An LAR ≥1.583 signals high 28-day mortality risk, necessitating intensified monitoring and potential ICU admission. For 90-day mortality, LAR near 1.423 serves as an early warning for high-risk patients and guides interventions. Continuous LAR monitoring aids management, but prospective studies are needed to confirm clinical utility.